Survival analysis and mortality predictors of COVID-19 across the six-wave pattern of the pandemic in Monastir, Tunisia : COVID-19 mortality predictors in Monastir across six waves.

Publication date: Jun 10, 2026

COVID-19 represents a serious health concern leading to considerable morbidity and mortality worldwide. The repercussion of COVID-19 was expected to be more severe in middle- and low-income countries. Few studies have examined survival patterns across six successive pandemic waves. The objective of this study was to analyze the survival rates during the first six waves of the pandemic in the Monastir governorate (Tunisia) and identify mortality predictors of COVID-19. We conducted a prospective cohort study encompassing all COVID-19 patients admitted to healthcare facilities in Monastir between March 2020 and March 2022, spanning six full waves of infection. Patients were monitored throughout their hospital stay. Data were gathered using a questionnaire carefully filled out by trained residents. Survival analysis was performed to compare outcomes across the different waves. Cox model employing a stepwise variable selection approach in multivariate survival analysis was utilized to assess the risk factors associated with COVID-19 deaths. COVID-19 waves occurred between March 2020 and March 2022, resulting in a total of 58,861 infections, 5176 hospitalizations, and 1109 deaths in hospitals. The 30-day survival rate decreased progressively, reaching its minimum during W4 and W5 at 30. 6% and 29. 5%, respectively. The 30-day cumulative in-hospital mortality probability among COVID-19 hospitalizations was 57. 4%. Based on Cox multivariate analysis, W4 and W5 demonstrated the highest mortality risk, with W3 and W6 showing a moderate and comparable level of risk, while W2 exhibited the lowest risk. Independent prognostic factors for early hospital death were age over 75 years (HR 3. 44- 95% CI 2. 62-4. 52), cancer (HR 1. 90-95% CI 1. 17-3. 01), and neurological symptoms (HR 1. 30-95% CI 1. 04-1. 62). Fever (HR 0. 69- 95% CI 0. 60-0. 81) and digestive symptoms (HR 0. 73- 95% CI 0. 56-0. 94) were associated with lower observed mortality. Advanced age, cancer and neurological symptoms are associated factors for in-hospital mortality during COVID-19. Our findings emphasize the importance of early identification and need for targeted interventions for high-risk patients to optimize care and improve survival rates. This six-wave longitudinal analysis provides a comprehensive overview of temporal changes in survival and mortality risk across successive pandemic phases, offering valuable evidence to inform preparedness and response strategies in similar settings. Not applicable.

Open Access PDF

Concepts Keywords
Healthcare COVID-19 waves
Pandemic Hospital
Tunisia Mortality
SARS-Cov-2
Survival analysis
Tunisia

Semantics

Type Source Name
disease MESH COVID-19
disease MESH infection
disease MESH death
disease MESH cancer
disease MESH Fever
disease MESH Long Covid
disease MESH Infectious Diseases
disease MESH Dis
pathway REACTOME Reproduction
disease MESH included
drug DRUGBANK Coenzyme M
disease MESH Severe Acute Respiratory Syndrome
disease MESH Middle East Respiratory Syndrome
disease MESH acute respiratory distress syndrome
disease MESH multiple organ failure
disease MESH heart failure
disease MESH kidney failure
disease MESH shock
disease MESH secondary infections
disease MESH anemia
disease MESH cardiac arrhythmias
disease MESH respiratory failure
disease MESH cardiovascular disease
disease MESH obesity
disease MESH hypertension
disease MESH atrial fibrillation
disease MESH face
disease MESH Emergency
disease MESH healthcare associated infections
disease MESH reinfection
disease MESH pneumonia
disease MESH asthenia
disease MESH dyspnea
disease MESH cough
disease MESH chest pain
disease MESH abdominal pain
disease MESH nausea
disease MESH vomiting
disease MESH diarrhea
disease MESH arthralgia
disease MESH myalgia
disease MESH headache
disease MESH confusion
disease MESH convulsions
disease MESH anosmia
disease MESH ageusia
disease MESH otalgia
disease MESH vertigo
disease MESH rhinitis
disease MESH strains
drug DRUGBANK Oxygen
disease MESH HRs

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *